Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Inclusion Criteria:

- Laboratory-confirmed diagnosis of COVID-19 by detection of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) RNA by Reverse transcription polymerase chain
reaction (RT-PCR) from any specimen respiratory

- Admitted to the hospital within 36 hours

- Oxygen saturation of hemoglobin by pulse oximetry at room air ≤94%

- For patients admitted WITH respiratory symptoms, enrollment must occur within 36 hours
of hospital admission. If the patient is admitted to the hospital with normal
saturations, but develops respiratory symptoms DURING their hospital stay, enrollment
may occur within 24 hours of desaturation to 94% or less on room air

- Understands the procedures and requirements of the study and provides written informed
consent and authorization for protected health information disclosure

Exclusion Criteria:

- Hypersensitivity to vadadustat or any of its excipients

- Placed on mechanical ventilation before randomization

- Hemoglobin above the gender-specific upper limit of normal (ULN) at randomization: 16
g/dL for females and 18 g/dL for males

- Patients who have erythrocytosis or polycythemia vera

- Patient taking Probenecid, lopinavir or ritonavir

- Women who are pregnant or breastfeeding, or positive pregnancy test before
randomization

- Patients not on maintenance dialysis with eGFC < 31 ml/min

- Patients who have received a solid organ transplant, heart, kidney, liver or lung

- Patients who are prisoners

- Patients who are currently Do Not Resuscitate (DNR) or Do Not Intubate (DNI)

- Patients with modified Rankin scale of 3 or greater

- Patient who are currently enrolled in any other interventional clinical trial